[ad_1]
“If it goes well, the first doses will be delivered to us by the end of the yearThus, the Minister of Health, Roberto Speranza, announced with optimism the arrival of the vaccine against the new coronavirus, developed by the University of Oxford, which will be produced by the pharmaceutical group Astrazeneca. But at night the cold shower came, with the first stop of trials around the world, decided to look at a possible serious side effect, found in some volunteer patients from the UK. The tests had reached phase 3 and the stop, Astrazeneca explained, was established by “standard review process to allow review of safety data“.
Thus, after the announcement of the arrival of the vaccine, the reverse came and the minister Robert hope it ends up in the viewer. Immunologist Antonella Viola commented on Facebook: “I shook my head skeptically when Minister Speranza announced the first doses for November, and sadly, she was right. Times get longer“A slap on the wrist for the Minister of Health also comes from Marco Cappato, treasurer of the Luca Coscioni association:”Those who shot random dates like ‘we will have the vaccine by …’ did not consider that problems can always occur, because that is how scientific research works.“. “The tabloid ads of a solution around the corner do not have a solid foundation“, also according to the immunologist Alberto Mantovani, scientific director of the Humanitas Clinical Institute of Rozzano (Milan)”.done“Commented virologist Ilaria Capua, writing on Twitter, referring to the suspension of the vaccine.
Sui Social There are also several comments from users, who criticize the minister for announcing the arrival of the antidote, without taking into account the experimentation phases and possible problems. A user remembers that the antidote to the setback is “the vaccine touted by Speranza who has signed a contract for 400 million doses as of the end of the yearCommenting on the news, there are also those who sarcastically point out that “it is not valid, Hope has already sold it”, while someone points out how “hasty” the Health Minister’s forecasts were.
The scientific world also stepped in to explain the implications of this setback. “News of the discontinuation of the Oxford vaccine trial confirms that there must be a lot going on in this matter prudent– explained the medical director of Spallanzani, Francesco Vaia- because it is the public health of billions of people, because we are talking about a pandemic. It also tells us that we should not be in a hurry and that the security phase is very delicate“. Therefore, the suspension of the trial has been approved. Positive opinion in the stop also by the infectious diseases specialist of the San Martino Polyclinic hospital in Genoa, Matteo Bassetti, according to whom the rupture”is the sign that companies are working seriously, transparently and verification the data. This is the strongest argument we can have against vaccine naysayers and non-vaxes who attacked that it would be marketed without evidence. Here, this is the best answer that could be given to you.“. Bassetti explains that”there was a problem and the company was not ashamed to say stoppiano and let’s see what happened“.
The “The reverse of the Oxford AstraZeneca vaccine is physiological and normal“also for Andrea Crisanti, Professor of Microbiology at the University of Padua, who specified a 24Mattino on Radio24: “It is not a stop, but a phase of classification, a vaccine has never been developed in a year“To get to the vaccine, in fact, we have to face a long and complex process”,involving about 100,000 people, the development of a vaccine takes about 5 years: it takes time“.
“The important thing is not to finish first, but to finish well in vaccine production“, also according to the immunologist Alberto Mantovani, scientific director of the Humanitas Clinical Institute of Rozzano (Milan)”.The stop could be due to a possible inflammatory response in one of the test subjects– explained Mantovani – Hope and caution are the two vectors that should guide the research of the new vaccine“.
Silvio Garattini, president of the Mario Negri Institute of Pharmacological Research in Milan, explains that the suspension “it is not a rejection“, why “if there is a suspicious case, we stop to understand if it is due to the product or due to situations involving patients “. This is a delicate phase and therefore “now we must avoid going into small details as much as possible and wait to see when the test study is completedIt is not possible to say how long it will take and if this pause could jeopardize all the experimentation but, Garattini concludes, “we must have confidence.”
